StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Getting excited for the week ahead

<< Previous

Bullboard Posts

Next >>

Comment by Bucky86on Mar 21, 2021 6:55pm

105 Views

Post# 32847768

RE:RE:RE:RE:RE:RE:Getting excited for the week ahead

Good points. I agree on both parts.
I do think that there is a monumental difference between launcing aristotle and launcing it properly.
To have it ready for market is meaningless to me/you/the world if they do not have significant significant partners and avenues. No more bullsh!t mythical compnaies like oncore etc.

If Aristotle isnt launced properly immediately this company is dead in the water. Their magic live saving tests are useless if they sell 50k a quarter of them like they did precovid.

fingers crossed

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing